Research programme: photodynamic therapy for cancer - Bluepharma/Universidade de Coimbra
Latest Information Update: 08 Mar 2014
At a glance
- Originator Bluepharma; Universidade de Coimbra
- Mechanism of Action Photosensitisers
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer